İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2019 · article

The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity

ISSN0301-4738
YÖKSİS OpenAlex Açık erişim · diamond
Yıl2019
Atıf12OpenAlex
Atıf9Semantic Scholar · 1 etkili
Yüzdelik%82,6
FWCI1,561,00 = dünya ortalaması
Scopus (SJR)Q3
WoS (JCR)Q4

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıIndian Journal of Ophthalmology
  • Katalog eşleşmesi (ISSN)Indian Journal of Ophthalmology
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

Purpose: Retinopathy of prematurity (ROP) is the leading cause of preventable blindness in premature infants. Antivascular endothelial growth factor (anti-VEGF) therapy has been used increasingly in treatment as a pharmacological alternative to laser therapy. In this study, we evaluate the results of low-dose anti-VEGF treatments. Methods: Design: Retrospective--observational study. Infants who had been evaluated for ROP disease between February 2016 and February 2017 were assessed. We retrospectively reviewed the ROP stages, treatment results, and complications. Laser photocoagulation (LPC) and intravitreal bevacizumab (0.16 mg IVB) were used for treatment and fundus fluorescein angiography (FFA) was also performed in some of the cases. Results: IVB was applied to 43 infants. A macular hole was seen in one infant's eye after IVB. LPC was applied to avascular areas in 21 infants. In three patients, persistence of the disease was observed after administration of a low dose of IVB. Additional LFK was performed in these patients. None of the infants who received LPC had any complications. Conclusion: IVB is increasingly becoming the first-line treatment for ROP. For severe ROP, 0.16 mg IVB is effective. Using LPC to treat avascular areas after 70 weeks' gestational age (GA) may decrease the risk of late recurrence and appears to be a safe treatment to use.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

12atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 1 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2023 RESULTS OF TWO CASES WITH DISTINCT COMPLICATIONS DUE TO INTRAVITREAL BEVACIZUMAB IN RETINOPATHY OF PREMATURITYAtıf 5 · OpenAlex

Yazarlar

3
  1. MÜBERRA AKDOĞAN AFYONKARAHİSAR SAĞLIK BİLİMLERİ ÜNİVERSİTESİ 1
  2. SADIK GÖRKEM ÇEVİK 2
  3. ÖZLEM ŞAHİN 3